Patients with a failed transplant face a higher mortality risk compared to those with a working graft, particularly in the ...
A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, ...
Rising early-onset cancer incidence has become a growing concern, but rates also have increased among individuals aged 50 years and older for many of the same malignancies.An international ...
The study results reflect the effect of surgery with lymph node dissection alone in patients with high-grade invasive bladder cancer.
In hormone-sensitive prostate cancer, an alternative dosing of docetaxel plus Nubeqa and ADT was associated with improvements in side effect rates.
In MIBC patients, ctDNA-guided, adjuvant atezolizumab treatment is associated with significant survival improvements over placebo.
Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients
(NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 IMvigor011 clinical trial in muscle-invasive bladder cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback